# Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)

> **NCT02825160** · — · COMPLETED · sponsor: **Bayer** · enrollment: 282 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Ventavis (Iloprost, BAYQ6256)

## Key facts

- **NCT ID:** NCT02825160
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-01
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-09-27
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02825160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02825160, "Non-interventional, Postauthorization Safety Study of Ventavis for Pulmonary Arterial Hypertension (PAH)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02825160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*